Puma Biotech plunges on drug side effects
Is Puma Biotechnology a Buy? | The Motley Fool
Puma Biotech shares slide after glimpse of trial data on cancer drug | Financial Times
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Exhibitor Puma Biotechnology 02-20 - Scripps CME Connection
Puma Biotechnology
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology Inc
Puma Biotechnology
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
Puma Biotechnology
PumaBiotech (@pumabiotech) / Twitter
Puma Biotech Gets $100M Loan to Boost Breast Cancer Drug - Los Angeles Business Journal
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Takeda farms out cancer drug alisertib to Puma Biotech -
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
